As They Look To The U.S., Celltrion And Hospira Win Approval For Remicade Biosimilars In Canada
This article was originally published in The Pink Sheet Daily
Executive Summary
The first biosimilar MAb approval in Canada could mean Korea’s Celltrion and its partner Hospira are getting closer to filing in the U.S.
You may also be interested in...
Celltrion Biosimilar Package Strong, But How Many Indications Will It Get?
Like Zarxio before it, Celltrion’s biosimilar infliximab product Inflectra is coming before a US advisory committee having received a glowing review from FDA staff; but the key question seems to be how many of Remicade's indications will it be able to extrapolate.
Hospira Targets First U.S. Biosimilar Filing In 2014
The generic specialty injectables firm expects to file a biosimilar version of Amgen’s Epogen in the U.S. in late 2014, potentially positioning it for its first U.S. biosimilar launch in late 2015.
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.